ArticlePloS one2021

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Janna Krueger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.